Thyroid function, glycemic control, and diabetic nephropathy in patients with type 2 diabetes over 24 months : prospective observational study
© 2023. The Author(s)..
BACKGROUND: The higher prevalence of thyroid dysfunction in type 1 diabetes patients has been well established, whereas it is a matter of debate whether that is also observed in type 2 diabetes patients. This study was conducted to reveal whether higher prevalence of thyroid dysfunction is observed in patients with type 2 diabetes.
METHODS: We examined thyroid functions and thyroid autoantibodies in 200 patients with type 2 diabetes and 225 controls, with 24 months follow up for those with type 2 diabetes.
RESULTS: Serum free triiodothyronine (fT3) levels and fT3/free thyroxine (fT4) ratio were significantly lower, while fT4 levels were significantly higher in patients with type 2 diabetes. The number of patients with thyroid dysfunction or patients positive for thyroid autoantibodies were not different between the two groups. The fT3/fT4 ratio was positively and negatively correlated with serum c-peptide and HbA1c levels, respectively, suggesting that the difference can be attributable to insulin resistance and diabetic control. In the follow-up observation, we found no significant correlation between basal thyrotropin (TSH), fT3, fT4 or fT3/fT4 ratio with the amounts of changes of HbA1c levels at 12 or 24 months after the basal measurements. There was a negative relationship between TSH levels and eGFR at baseline measurements, but TSH levels did not seem to predict future decline of eGFR levels. No relationship was observed between urine albumin/ g‧cre levels and thyroid function.
CONCLUSION: Thyroid dysfunction and thyroid autoantibodies were not different in prevalence between patients with type 2 diabetes and controls, although in patients with type 2 diabetes, the fT3/fT4 ratio was decreased. Basal thyroid function did not predict future diabetes control or renal function within 24 months of follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
BMC endocrine disorders - 23(2023), 1 vom: 10. Juli, Seite 146 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iwakura, Hiroshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 24.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12902-023-01393-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359312373 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359312373 | ||
| 003 | DE-627 | ||
| 005 | 20231226080613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12902-023-01393-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359312373 | ||
| 035 | |a (NLM)37430240 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iwakura, Hiroshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thyroid function, glycemic control, and diabetic nephropathy in patients with type 2 diabetes over 24 months |b prospective observational study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 24.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: The higher prevalence of thyroid dysfunction in type 1 diabetes patients has been well established, whereas it is a matter of debate whether that is also observed in type 2 diabetes patients. This study was conducted to reveal whether higher prevalence of thyroid dysfunction is observed in patients with type 2 diabetes | ||
| 520 | |a METHODS: We examined thyroid functions and thyroid autoantibodies in 200 patients with type 2 diabetes and 225 controls, with 24 months follow up for those with type 2 diabetes | ||
| 520 | |a RESULTS: Serum free triiodothyronine (fT3) levels and fT3/free thyroxine (fT4) ratio were significantly lower, while fT4 levels were significantly higher in patients with type 2 diabetes. The number of patients with thyroid dysfunction or patients positive for thyroid autoantibodies were not different between the two groups. The fT3/fT4 ratio was positively and negatively correlated with serum c-peptide and HbA1c levels, respectively, suggesting that the difference can be attributable to insulin resistance and diabetic control. In the follow-up observation, we found no significant correlation between basal thyrotropin (TSH), fT3, fT4 or fT3/fT4 ratio with the amounts of changes of HbA1c levels at 12 or 24 months after the basal measurements. There was a negative relationship between TSH levels and eGFR at baseline measurements, but TSH levels did not seem to predict future decline of eGFR levels. No relationship was observed between urine albumin/ g‧cre levels and thyroid function | ||
| 520 | |a CONCLUSION: Thyroid dysfunction and thyroid autoantibodies were not different in prevalence between patients with type 2 diabetes and controls, although in patients with type 2 diabetes, the fT3/fT4 ratio was decreased. Basal thyroid function did not predict future diabetes control or renal function within 24 months of follow-up | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Diabetic nephropathy | |
| 650 | 4 | |a Glycemic control | |
| 650 | 4 | |a Thyroid function | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 700 | 1 | |a Takagi, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Inaba, Hidefumi |e verfasserin |4 aut | |
| 700 | 1 | |a Doi, Asako |e verfasserin |4 aut | |
| 700 | 1 | |a Ueda, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Uraki, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Takeshima, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Furukawa, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishibashi, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Shuhei |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuno, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Nishi, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Furuta, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Taka-Aki |e verfasserin |4 aut | |
| 700 | 1 | |a Akamizu, Takashi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC endocrine disorders |d 2001 |g 23(2023), 1 vom: 10. Juli, Seite 146 |w (DE-627)NLM115892036 |x 1472-6823 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:10 |g month:07 |g pages:146 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12902-023-01393-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 10 |c 07 |h 146 | ||